Cannabis Chemotypes: The 1% of the Pharmacopoeia

The European Pharmacopoeia is the official reference standard for medicines in the EU. In its most recent edition (11.5), it establishes a fundamental scientific classification of cannabis based on its chemical composition or "chemotypes". This standard officially recognizes the 1% THC threshold for CBD-rich varieties.

Book of the European Pharmacopoeia and botany — The European Pharmacopoeia defines the quality and safety standards for cannabis products in the Union.
📷 AECANI Visual Lab

Pharmacological Standard

The European Pharmacopoeia does not use the 0.2% threshold. To define what is a CBD-dominated plant, it uses the scientific threshold of 1% of THC.

The 3 Official Chemotypes

According to the monograph Ph. Eur. 3028, cannabis is divided into

Chemotype I

THC-Dominant

High THC, low or no CBD. This is narcotic or traditional medicinal cannabis.

Chemotype II

Intermediate

Balanced presence of THC and CBD (ratio close to 1:1).

Chemotype III

CBD-Dominant

CBD predominates over THC. Limit: Maximum 1% THC.

✦

Why is this definition important?

This classification is the legal and scientific basis for

Quality Control: Allows laboratories to certify products with European standards
Legal Certainty: Unlinks CBD (fiber/industrial) chemotype from narcotic cannabis
Harmonization: This is the criterion to be followed by all Member States for the pharmaceutical and wellness industry

Molecular diagram of cannabinoids — Chemical differentiation between CBD and THC is the key to proportional and fair regulation.
📷 AECANI Visual Lab

Harmonization Opportunity

While the European Pharmacopoeia recognizes 1% for the CBD chemotype, the Spanish administrative framework currently applies 0.2% as an operational criterion. This difference raises opportunities for harmonization based on scientific criteria.

Towards a Real Standard

AECANI advocates harmonization of the industrial sector with the criteria of the European Pharmacopoeia. If 1% is safe for medicines, it is also safe for the agricultural and industrial sector

"
There is an opportunity for harmonization between the industrial sector and the European Pharmacopoeia criteria, which defines the CBD-dominant chemotype as non-narcotic.

📚 References

European Pharmacopoeia (Ph. Eur.) 11.5 - Monograph 3028 "Cannabis Flower"
EDQM - European Directorate for the Quality of Medicines & HealthCare